Mycophenolate Mofetil API Producers and Mycophenolate Mofetil API Market Trend

Mycophenolate Mofetil is indicated for prophylaxis of organ rejection in patients and treatment of primary and secondary glomerulopathies, uveitis, Crohn's disease, rheumatoid arthritis, and lupus.

The global Mycophenolate Mofetil API market size was USD 82 million in 2017, growing to USD 115 million in 2022, with a CAGR of 7.0% from 2017 to 2022. The global Mycophenolate Mofetil API market size is expected to reach USD 164 million in 2027, with a CAGR of 7.4% from 2022 to 2027.

Figure 2017-2027 Global Mycophenolate Mofetil API Market Size (Million USD) and CAGR

Mycophenolate Mofetil API suppliers include Concord Biotech, Teva Pharmaceutical Industries Ltd. (Teva), Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB), Chempro Pharma Pvt Ltd, RPG Life Sciences Ltd., Srini Pharmaceuticals Ltd., Livzon New North River Pharmaceutical Co., Ltd., Chongqing Daxin Pharmaceutical Co., Ltd., Shanghai Acebright Pharmaceuticals Group Co., Ltd., etc.

Currently, Europe is the largest Mycophenolate Mofetil API consumption region accounting for 35% volume share, followed by comparable consumption in APAC and North American markets.

Mycophenolate Mofetil formulations are available in tablet, capsule and injectable.